Protai

Company Overview

Snapshot

Founded in July 2021 by Eran Seger and Kirill Pevzner, Protai operates with 11–50 employees. The company has raised $20 million across two funding rounds from two investors. In May 2026, Protai was recognized as one of the Most Innovative Life Science Startups at Biomed Israel 2026.

Business overview

Protai is a Health Tech & Life Sciences company that has developed an end-to-end AI-based platform designed to map the course of disease at the protein level. This technology enhances the observation of cellular function and aims to improve the drug discovery process. The company builds machine learning models that combine deep proteomics to identify up to 1 million proteoforms, including post-translational modifications, protein-protein interactions, quantifications, and different structural populations of proteins. Protai operates within the Pharma & Medical Biotechnology sector, specifically focusing on Drugs Discovery & Development, and serves the Life Sciences and Pharmaceutical industries.

Strategic signal

In May 2026, Protai was awarded as one of the Most Innovative Life Science Startups at Biomed Israel 2026. This recognition signals strong industry validation for Protai's AI-driven drug discovery platform and its potential to significantly impact the pharmaceutical landscape, highlighting its forward trajectory in innovation and market relevance.

Company Intelligence Q&A

What significant recognition did Protai receive in May 2026?

In May 2026, Protai was awarded as one of the Most Innovative Life Science Startups at.

What was Protai's focus at global conferences in February 2026?

In February 2026, Protai showcased its groundbreaking AIMS drug discovery platform and best-in-class PRT001 KAT6A degrader results at various global scientific conferences.

What was Protai's focus at global conferences in October 2025?

In October 2025, Protai showcased breakthroughs in structural proteomics and AI-driven drug discovery at four major scientific conferences.

What strategic move did Protai make regarding its advisory board in October 2025?

In October 2025, Protai strengthened its advisory board by adding three leading scientists to drive drug discovery and support its expansion into immunology and inflammation.

When did Protai raise its initial Seed round?

In January 2022, Protai raised an initial Seed round with participation from Grove Ventures.